तुलना करने के लिए मीट्रिक्स | 340450 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध340450पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 30.1x | −6.6x | −0.4x | |
PEG अनुपात | 0.00 | 0.01 | 0.00 | |
क़ीमत/बुक | 2.0x | 1.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 5.0x | 3.9x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 34.6% | 54.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 10.5% | 7.0% | अनलॉक करें |
GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing. The company also provides ai-CANCERCH, an AI algorithm-based multi-cancer early screening test; Jins Sketch, a genetic test for personalized nutrition; Genome Health and Risk Screen that identifies various disease-susceptibility genes; Green Biome for human symbiotic microorganism genetic analysis service; Genome Screen, an optimal genetic test for preemptive action; Telorisk, an indicator of biological age; and drug compatibility DNA test. In addition, it offers G-NIPT, a noninvasive fetal chromosomal abnormality screening test; Prenatal CMA, a diagnostic test for fetal chromosomal abnormalities with higher diagnostic value; i-screen for newborn genetic screening; and dd-cfDNA, a single nucleotide polymorphism test of cell-free nucleic acid derived from organ transplant donors. The company was founded in 2013 and is based in Yongin-si, South Korea.